Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 1/20 | 0.58 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.57 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19011425 | 0.84 | ALDH1A1 (0.64) | KMT2AALDH1A1MEN1CYP2C9CYP3A4 | |
| SCHEMBL14606617 | 0.84 | ALDH1A1 (0.68) | KMT2AALDH1A1MEN1CYP2C9CYP3A4 | |
| SCHEMBL6626965 | 0.84 | ALDH1A1 (0.56) | KMT2AALDH1A1MEN1CYP2C9CYP3A4 | |
| SCHEMBL14606672 | 0.84 | ALDH1A1 (0.68) | KMT2AALDH1A1MEN1CYP2C9CYP3A4 | |
| SCHEMBL28113177 | 0.84 | KMT2A (0.67) | KMT2AALDH1A1MEN1CYP2C9CYP3A4 | |
| SCHEMBL7698041 | 0.84 | KMT2A (0.67) | KMT2AALDH1A1MEN1CYP2C9TSHR | |
| SCHEMBL8396377 | 0.83 | GBA1 (0.83) | KMT2AALDH1A1MEN1GBA1SMN1; SMN2 | |
| SCHEMBL7886816 | 0.83 | GBA1 (0.83) | KMT2AALDH1A1MEN1GBA1SMN1; SMN2 | |
| SCHEMBL23052369 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1MEN1CYP2C9TSHR | |
| SCHEMBL7698803 | 0.83 | KMT2A (0.62) | KMT2AALDH1A1MEN1CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924125-A | Method for preparing sulfonamide derivative through visible light catalysis without metal participation | 苏州大学 | 2024-04-26 | — | — | CN | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-20210060995-A1 | THERMAL TRANSFER RECORDING SHEET | CANON KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) | 2017-06-22 | — | — | US | disclosed |
| CN-104418678-B | A kind of method of synthetic N-alkyl sulfonamide derivatives | NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2016-05-18 | — | — | CN | disclosed |
| CN-104418678-A | Method for synthesizing N-alkyl sulfonamide derivative | UNIV NANJING SCIENCE & TECH | 2015-03-18 | — | — | CN | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2002057220-A1 | HYDRAZIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | ABCD3, CFTR, ADSL | KMT2A 3531/4885ALDH1A1 1243/4885MEN1 4279/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | KMT2A 2032/4885ALDH1A1 728/4885MEN1 4642/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | KMT2A 1380/4885ALDH1A1 381/4885MEN1 1700/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | KMT2A 1442/4885ALDH1A1 528/4885MEN1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.